Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53212
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Type: Journal article
Title: Ibudilast in healthy volunteers: Safety, tolerability and pharmacokinetics with single and multiple doses
Author: Rolan, P.
Gibbons, J.
He, L.
Chang, E.
Jones, D.
Gross, M.
Davidson, J.
Sanftner, L.
Johnson, K.
Citation: British Journal of Clinical Pharmacology, 2008; 66(6):792-801
Publisher: Blackwell Publishing Ltd
Issue Date: 2008
ISSN: 0306-5251
1365-2125
Statement of
Responsibility: 
Paul Rolan, Jacqueline A. Gibbons, Lin He, Eppie Chang, Drew Jones, Matthew I. Gross, Jennifer Bahr Davidson, Laura M. Sanftner & Kirk W. Johnson
Abstract: AIMS: To investigate the safety, tolerability and pharmacokinetics (PK) of ibudilast after a single-dose and a multiple-dose regimen. METHODS: Healthy adult male (n = 9) and female (n = 9) volunteers were evaluated over a 17-day stay in a Phase 1 unit. Subjects were randomized 1 : 3 to either oral placebo or ibudilast at 30-mg single administration followed by 14 days of 30 mg b.i.d. Complete safety analyses were performed and, for PK, plasma and urine samples were analysed for ibudilast and its major metabolite. RESULTS: Ibudilast was generally well tolerated. No serious adverse events occurred. Treatment-related adverse events included hyperhidrosis, headache and nausea. Two subjects discontinued after a few days at 30 mg b.i.d. because of vomiting. Although samples sizes were too small to rule out a sex difference, PK were similar in men and women. The mean half-life for ibudilast was 19 h and median T(max) was 4-6 h. Mean (SD) steady-state plasma C(max) and AUC(0-24) were 60 (25) ng ml(-1) and 1004 (303) ng h ml(-1), respectively. Plasma levels of 6,7- dihydrodiol-ibudilast were approximately 30% of the parent. CONCLUSIONS: Ibudilast is generally well tolerated in healthy adults when given as a single oral dose of 30 mg followed by 30 mg b.i.d. (60 mg day(-1)) for 14 days. Plasma PK reached steady state within 2 days of starting the b.i.d. regimen. Exposure to ibudilast was achieved of a magnitude comparable to that associated with efficacy in rat chronic pain models.
Keywords: human volunteers; ibudilast; pharmacokinetics; Phase 1; safety; tolerability
RMID: 0020083746
DOI: 10.1111/j.1365-2125.2008.03270.x
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.